Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks

Sana Biotechnology, Inc.

HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.
Cash $152.5M at Dec 31, 2024; cash runway expected into 2026.
Net loss $49.1M in Q4 2024 vs $88.1M in Q4 2023; full year 2024 net loss $266.8M.
Enrolling GLEAM (SC291 autoimmune) and VIVID (SC262 B-cell cancers); data expected in 2025.
Appointed Dhaval Patel as CSO and Tricia Stewart as CPO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.